
Budget 2025: Although the Nifty Pharma Index is 9 % lower in the year in January, market reforms are high for the overall pharmaceutical sector and is seen with approach and hopes for contract drug research. ۔
1. The scheme extension for contract research and manufacturing
Leaders of Sanjin International’s MD and CEO Jonathan Hunt said, “I’m going to wait and see what is in the budget, but in general, I think we have in India in recent years. I have paid more attention to the government on my industry, especially the PLI scheme with the pharmaceutical industry. They have done a lot in recent years and they can do more and more to research contract (CDMO Business – tradition, according to tradition, its manufacturing generic industry is being focused more, but our industry grows. Many opportunities have been found and I will see it.
Dr. Saloni Wag, Managing Director Sophia Life Science, also said that promoting domestic manufacturing is equally important to reduce import dependence. The extension of the LinkedIn Printing (PLI) scheme and the offer to contract research organizations (CROs) can reinforce India’s manufacturing base.
2. Easy to do business
Although the PLI scheme is an incentive, Hunt’s hopes are helping to create the environment in the government so that the bureaucracy and the easing of business can be further reduced.
Tating out operational challenges, such as section 194R, will also smooth the process, according to the wag, as well.
3. Priority to research and development
Wag said that research and development must be given priority. 10 % of the National Research Fund allocating life science and restoring 200 % weight deduction for R&D costs will encourage modern innovation, India’s global competitiveness will be strengthened, and drug discovery. Will be accelerated.
“The union’s budget reaches a significant moment for the 2025-26 Indian pharmaceutical industry, which is trying to achieve $ 120-130 billion by 2030 and $ 450 billion by 2047,” Dr. Wag said. Budget can be done.
This budget is a unique opportunity to contribute to the vision of a strong pharmaceutical ecosystem, ‘Victim India’ and ensure that India delivers and guidance globally.
Withdrawal: The views and recommendations given in this article are from individual analysts. They do not represent the ideas of the mint. We advise investors to check with certified experts before taking any investment decision.